Cryo-EM structure of active GPR65 leadXpro has just elucidated the world’s first structure of a proton-sensing GPCR target.
ABOUT leadXpro
Welcome to leadXpro, where we specialize in structure-based drug discovery for membrane proteins. Our team of experts brings together knowledge in membrane protein science, pioneering technologies in structural biology, and expertise in ligand design and characterization to help our clients develop new and innovative therapies.
At leadXpro, we are dedicated to helping our clients unlock the potential of membrane proteins to improve human health. Our research covers a range of membrane proteins, including GPCRs, ion channels, transporters, and enzymes, giving us a unique and comprehensive perspective on the drug discovery target space.
But we don’t just stop at research. As a contract research partner, we offer a variety of services and partnership models to a growing number of pharmaceutical, biotech, and academic partners. Our flexible approach allows us to work with clients at every stage of their drug discovery project, from hit finding and validation, to structure-based optimization of preclinical compounds.
So if you’re looking to make a breakthrough in drug discovery, look no further than leadXpro. Contact us today to learn more about how we can help you achieve your goals.
See our technology platform
THERAPEUTICS
Using its unique technology platform, leadXpro is developing proprietary preclinical compounds with high efficacy and specificity.
See our pipeline
leadXpro Timeline
Latest updates about leadXpro
First CrySol VitroJet in Switzerland
We are thrilled to announce that leadXpro has extended its cryo-EM facility with the latest technology in sample preparation solution, the VitroJet. This cutting-edge technology is the first of its kind in Switzerland.
leadXpro has just elucidated the world’s first structure of a proton-sensing GPCR target
To date, no structural information has been reported for the entire H+ activated GPCR family.
Colocalized targeting of TGF-beta and PD-L1 by bintrafusp alfa elicits distinct antitumor responses
In collaboration with Merck/Serono, leadXpro confirmed the colocalization aspect of the mode of action of bintrafusp alfa using Cryo-Electron Microscopy
Our partners
